Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice

Sherief Abd-Elsalam; Rehab Badawi; Sally ElnawasanyMohamed YousefLoai MansourNehad HawashReham A. ElkhoulyShaimaa SolimanAmal SelimAbdelrahman KobtanAsem Elfert

首页> 外文期刊>Infectious disorders drug targets >Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice

【24h】

Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice

机译：Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

BackgroundandAims: Hepatitis C virus infection is a major public health problem in Egyptwith a risk for morbidity and mortality due to chronic liver disease complications. Worldwide, Egypthas the highest prevalence of HCV infection with the overall prevalence of about 14.7. The aim ofthis study was to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) plus PegylatedInterferon (Peg- IFNa) and Ribavirin (RBV) in Egyptian patients with chronic hepatitis C virus(HCV) infection.Methods: This study was carried out in 1200 patients with chronic hepatitis C virus infection who wereeligible for interferon therapy. They were treated with the triple therapy of sofosbuvir 400 mg oncedaily, Peg-INF subcutaneous injection weekly for 12 weeks in combination with oral weight-basedribavirin. The primary outcome measures were the number of patients with successful eradication ofthe virus evidenced by the sustained virologic response (SVR) at 12 Weeks. After discontinuation ofTherapy (SVR12), the secondary outcome measures were the incidence of adverse effects associatedwith the tested HCV therapy.Result: The mean age of the patients was 49.32 ± 6.97 years. 45.9 of them were males and 54.1were females.70 patients (5.8) had a history of previous HCV treatment. ''1077 (89.8)'' of patientsachieved successful eradication of virus while ''106 (8.8)'' were resistant to treatment and ''17 (1.4)''stopped treatment. Good predictors of response to the triple therapy were female gender, treatmentnaive and non-cirrhotic patients.Conclusion: The triple regimen of Pegylated interferon, sofosbuvir plus ribavirin is safe and effectivein the treatment of Egyptian patients with hepatitis C virus and is associated with real-life SVR12 ratesof 89.8.

著录项

来源
《Infectious disorders drug targets》 |2019年第2期|179-184|共6页
作者
Sherief Abd-Elsalam; Rehab Badawi; Sally ElnawasanyMohamed YousefLoai MansourNehad HawashReham A. ElkhoulyShaimaa SolimanAmal SelimAbdelrahman KobtanAsem Elfert;
展开▼
作者单位

Tanta University, Department of Tropical Medicine, Tanta;

Menoufia University, Department of Public Health and Community Medicine Tanta, Tanta;

Tanta University, Department of Internal Medicine, Tanta;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类药学;
关键词
Hepatitis C virus; clinical practice; treatment; Egypt; infection; interferon;

Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice

摘要

著录项

相关主题

期刊订阅